* Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. * The approved ANDA is therapeutically equivalent to Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC. * Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. * With this approval, Alembic now has a cumulative total of 230 ANDA approvals from USFDA, comprising 210 final approvals and 20 tentative approvals.
